The rate of the HR+/HER2− subtype is six times higher than the triple-negative breast cancer rate (13.1) and the HR+/HER2+ breast cancer rate (13.4), and more than 16 times higher than the HR−/HER2+ breast cancer rate (5.5) around the world (Graph 9). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.